HSF News

Frequently Asked Questions about Hidradenitis Suppurativa (HS) and COVID-19

Updated April 6th, 2020

This content was generated from a podcast.

FOR PROVIDERS

What is COVID-19, and how is it different from the flu or other infections we have dealt with?

• Coronaviruses are a large group of RNA viruses that cause respiratory illnesses. Mostly, COVID19
causes mild upper respiratory tract symptoms. Most morality occurs when the lower respiratory
tract is involved, with cytokine storm causing ARDS and shock.
• The novel coronavirus (SARS-CoV-2) occurs naturally, enters the body through respiratory
droplets (either inhaled or by touching mouths, nose, eyes) and causes the illness called COVID-
19.
• Coronavirus enters the cells of the lung via ACE receptors.
• Coronavirus can survive in the air for up to 8 hours, and can last for up to 72 hours on some
surfaces.
• Coronavirus is structurally different from the influenza virus. Compared to the seasonal flu, the
novel coronavirus causes more severe illness and has higher death rates (estimated to be 10x
higher).
• Based on limited data, all age groups can contract COVID-19. However, some subsets of people
are at higher risk of severe illness or death than others, including:
o Adults over age 65 years
o Infants
o People with heart, lung or kidney disease
o People with cancer undergoing cancer treatment
o People on immunosuppressive medications
• Symptoms of COVID-19 include fever, shortness of breath, cough, loss of smell, loss of taste, and
uncommonly nausea, vomiting, diarrhea. However, many people infected with this virus can
harbor and spread infection without any symptoms.
• HS itself does not appear to be a specific risk factor for COVID-19. However, if someone has any
of the associated comorbidities listed above or is on immunosuppressive medications, they may
have increased risk for developing severe illness if infected with the novel coronavirus.

Read more
Research Summary

New drug shows promise for Hidradenitis Suppurativa treatment

An early study for a new injectable treatment shows improvement in Hidradenitis Suppurativa (HS) activity and pain scores while demonstrating safety. Dr. Alice Gottlieb of Icahn School of Medicine at Mount Sinai, New York led the research investigating the results of bermekimab use in 42 patients with Hidradenitis Suppurativa. The results were recently published in the Journal of Investigative Dermatology.

Read more
Grants & Scholarships

2020 Danby HSF Research Grant Funding Opportunities

The Hidradenitis Suppurativa Foundation (HSF) is seeking grant applications that encourage research into the disease hidradenitis suppurativa (HS). The goal is to stimulate the development of new research programs in the field of HS capable of competing for long-term funding from the National Institutes of Health or other agencies in the future.

If you would like to submit your proposal, please follow the instructions here: 2020 Danby Grant Program Details

Anticipated number of awards: 1-3 new grants may be awarded in 2020. Awards are contingent upon the availability of funds and the receipt of sufficiently meritorious applications.

Budget: Applicants may request up to $10,000 (direct costs only) per year.

Read more
Events

2018 DPAF 5K Run/Walk Honors HS Foundation

The DPAF 5K Run/Walk honored the HS Foundation during the SDPA’s Annual Summer Conference in Seattle this past July with a very generous donation, raised through a combination of funds raised for the walk/run itself and through a matching grant from DPAF.  The event was their largest to date and had enthusiastic buy-in from SDPA members, conference attendees, their leaders, and their partners.

Read more
Grants & Scholarships

Announcing New 2019 Danby Hidradenitis Suppurativa Research Grant Program

Request for Proposals

Purpose: The Hidradenitis Suppurativa Foundation (HSF) is seeking grant applications that encourage research into the disease hidradenitis suppurativa (HS). The goal is to stimulate the development of new research programs in the field of hidradenitis suppurativa capable of competing for long-term funding from the National Institutes of Health or other agencies in the future.

Anticipated number of awards: 1-2 new grants may be awarded in 2019. Awards are contingent upon the availability of funds and the receipt of sufficiently meritorious applications.

Budget: Applicants may request up to $10,000 (direct costs only) per year.

Read more
Grants & Scholarships

UCSF Dermatology Post-Doctoral Fellowship in Clinical Research

The UCSF Department of Dermatology’s Program for Clinical Research is thrilled to announce the availability of a 1-2 year postdoctoral research fellowship for starting July 1st 2018.

The primary areas of interest include epidemiology, public health and investigator-initiated clinical trials. The postdoc would join a dynamic research team that works on a wide range of topics: inflammatory skin diseases, hidradenitis suppurativa, atopic dermatitis, geriatric dermatology, skin cancer, and the use of social media in medicine.

Read more
Grants & Scholarships

Abbvie Immunology Scholarship Overview

The scholarship is available to students living with inflammatory diseases*, including Hidradenitis Suppurativa, who are seeking an undergraduate or graduate degree from an accredited US university/college or trade school, and who plan to enroll for the 2018-2019 school year.

  • Scholarships of up to $15,000 each will be awarded, dependent upon the type of degree pursued.
  • Applicants will be judged based on academic excellence, extracurricular activities, written response to an essay question, and letter of reference.
Read more
  • 1
  • 2
Back to Top